Efficient Market Hypothesis on the blockchain: A social‐media‐based index for cryptocurrency efficiency
Financial Review · 2024-08 · 59 (3) · 807-829
DOI: 10.1111/fire.12387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Financial Review, online erschienen am 23.03.2024. Verfasst von Efstathios Polyzos und 2 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: Zayed University.
Abstract (Originalsprache)
This paper proposes the use of social media as a proxy for financial information. Using an extended sample of 53,580,759 tweets and employing text analysis tools (Latent Dirichlet Allocation and Term Frequency–Inverse Document Frequency), we determine the information being exchanged on any given day. We train machine‐learning classifiers and forecast crypto price movements for more than 8000 cryptocurrencies and gauge market efficiency through successful forecasts based on public information. We propose various metrics of market efficiency for cryptocurrency assets and demonstrate that market efficiency is higher during the first 6 months after the Initial Coin Offering. We also examine the efficiency behavior of individual currencies during crisis periods.
Förderung
- Zayed University
Zitieren
APA
Polyzos, E., Rubbaniy, G., & Mazur, M. (2024). Efficient Market Hypothesis on the blockchain: A social‐media‐based index for cryptocurrency efficiency. Financial Review, 59(3), 807-829. https://doi.org/10.1111/fire.12387
Vancouver
Polyzos E, Rubbaniy G, Mazur M. Efficient Market Hypothesis on the blockchain: A social‐media‐based index for cryptocurrency efficiency. Financial Review. 2024;59(3):807-829. doi:10.1111/fire.12387
BibTeX
@article{Polyzos2024,
author = {Polyzos, Efstathios and Rubbaniy, Ghulame and Mazur, Mieszko},
title = {Efficient Market Hypothesis on the blockchain: A social‐media‐based index for cryptocurrency efficiency},
journal = {Financial Review},
year = {2024},
volume = {59},
number = {3},
pages = {807--829},
doi = {10.1111/fire.12387}
}
EUVIMED